August 29th 2023
The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.
August 24th 2023
Reduction in levels of 4 biomarkers was correlated with lower risk of composite cardiorenal outcomes in the CREDENCE trial, suggesting use of the panel to augment current risk assessment tools.
August 4th 2023
A daily dose of clinical news on Patient Care you may have missed.
July 31st 2023
Among persons with hypertension and T2D with albuminuria, nearly two-thirds currently go undetected, a significant barrier to diagnosis and treatment of CKD.
July 17th 2023
Factors positively associated with a timely first OAC Rx among the 41.3% who received one included male sex, certain comorbidities, other current medications, and obesity.
FDA Awards De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Decline in Kidney Function in Adults with Type 2 Diabetes and Early-Stage Kidney Disease
KidneyIntelX.dkd, a first-in-class AI-enabled prognostic test, stratifies risk of DKD progression in 5 years and is specific for early stage disease.
Daily Dose: HF, CV Benefit of SGLT-2 Inhibition Consistent in T2D, CDK, HF
Your daily dose of clinical news you may have missed.
SGLT-2 Inhibitor HF, CV Benefit Found Consistent Across Populations with T2D, CKD, HF
SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.
For Unknown Causes of Kidney Disease, Genetic Testing Holds Promise
A recent American Kidney Fund survey of 300 primary care and specialty clinicians found ~15% of their patients had kidney disease of unknown origin.
Daily Dose: Finerenone Reduces CKD-associated CV Risk in Patients with T2D
Finerenone Reduces CKD-associated Composite Cardiovascular Risk in a New Subanalysis of FIDELITY Trial
Finerenone was associated with a decrease in composite CV risk in patients with CKD, T2D, eGFR of ≥25, and moderately to severely increased albuminuria.
Seen in the ED: Intractable Vomiting in a Young Woman
The patient is in her mid-20s and other than an intermittent mild headache she denies any other pain and has no fever. Can you Dx based on the CT?
FDA Approves SGLT-2/1 Inhibitor Sotagliflozin, Grants Broad Heart Failure Indication
The novel co-inhibitor of sodium glucose cotransporter-1/2 proteins will be available by the end of June 2023, according to Lexicon Pharmaceuticals.
Improved Diabetes and Kidney Function Control With KidneyIntelX
Drs Aide Vega and Fernando Carnavali highlight the increased control in both diabetes and kidney function with the use of KidneyIntelX in patients with DKD.
Referral of High- and Low-Risk Groups in DKD
Aida Vega, MD, and Fernando Carnavali, MD, discuss the KidneyIntelX study and the rates of referrals of high-risk DKD patients to specialist care.
KidneyIntelX in DKD Study Population Characteristics
Aida Vega, MD, and Fernando Carnavali, MD, review the population characteristics of a study involving the use of KidneyIntelX in DKD.
Use of KidneyIntelX in Patients With DKD
Experts in diabetic nephropathy present a study of the use of the KidneyIntelX test in patients with DKD.
Role of DKD Progression Screening Tools
Experts review the role of the urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) in current DKD progression screening practices.
Current Screening Guidelines for DKD
Aida Vega, MD, and Fernando Carnavali, MD, discuss the limitations of the tools available to clinicians to screen for DKD, such as Kidney Disease: Improving Global Outcomes (KDIGO).
Prevalence of Diabetic Kidney Disease (DKD)
Fernando Carnavali, MD, comments on the prevalence of diabetic kidney disease (DKD) in the United States, the financial burden on patients and the healthcare system, as well as the importance of early detection of kidney disease in patients with diabetes.
Patients with CVD and Type 2 Diabetes and Chronic Kidney Disease are at Extremely High Risk for MACE
ACC 2023. Type 2 diabetes and CKD in patients with CVD are mutually independent predictors of MACE, concluded authors of a new study.
The Importance of Connecting Patients with ADPKD with Each Other
Peer mentor programs can provide support for patients, especially when it comes to family planning and parenthood.
Empagliflozin Reduced Risk of Renal Disease Progression, CV Death Across CKD Spectrum in EMPA-KIDNEY
Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.
Exercise Training Program Found to Improve Cardiorespiratory Fitness in Older Adults with Advanced CKD
In a study of nearly 100 adults with CKD stages G3b-4 and medical comorbidity, a 12-month exercise program was found safe and improved physical functioning.
ADA 2021: Baseline Insulin Use May not Impact Benefits of Finerenone in Patients with CKD, T2D
ADA 2021. A subgroup analysis of the FIDELIO-DKD trial showed that finerenone use was beneficial regardless of baseline insulin use among patients with T2D and CKD.
ADA 2021: Use of Dapagliflozin Decreases Risk of Diabetes in Patients with CKD
ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.
FDA Approves Dapagliflozin to Treat Chronic Kidney Disease in Adults at Risk of Progression, Regardless of Diabetes Status
Dapagliflozin is the first SGLT-2 inhibitor to receive FDA approval for the treatment of CKD, regardless of diabetes status.
Kidney Week: Dapagliflozin Renoprotective, Cardioprotective in CKD Patients
Dapagliflozin is renoprotective and cardioprotective in chronic kidney disease patients, suggests a secondary analysis of the DAPA-CKD trial presented at Kidney Week 2020.
2 Clarke Drive Cranbury, NJ 08512